SSRIs: Applications in inflammatory lung disease and implications for COVID-19.

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Immunology

Background:

• COVID-19 causes severe lung inflammation via pathways involving NF-κB, STAT3, and cytokines like IL-6.
• Pulmonary diseases such as ARDS and COPD share inflammatory mechanisms with COVID-19.

Purpose of the Study:

• To review the anti-inflammatory properties of selective serotonin reuptake inhibitors (SSRIs).
• To discuss the potential clinical utility of SSRIs in managing severe pulmonary manifestations of COVID-19.

Main Methods:

• Comparative analysis of lung inflammation pathogenesis in COVID-19, ARDS, and COPD.
• Review of SSRI mechanisms targeting inflammatory pathways.
• Discussion of SSRI applications for COVID-19-associated lung disease.

Main Results:

• SSRIs inhibit proinflammatory transcription factors (NF-κB, STAT3).
• SSRIs downregulate inflammatory cytokines (IL-6, IL-8, TNF-α, IL-1β) and reduce lung tissue damage.
• SSRIs directly suppress inflammatory cells, including T cells, macrophages, and platelets.

Conclusions:

• SSRIs demonstrate multi-level anti-inflammatory effects relevant to COVID-19 pathogenesis.
• SSRIs represent a potential therapeutic strategy for severe COVID-19-associated inflammatory lung disease.